Fortress Biotech, Inc.
FBIO
$2.31
$0.093.83%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.63% | 13.43% | |||
| Total Other Revenue | -97.85% | -56.84% | |||
| Total Revenue | -8.80% | 7.42% | |||
| Cost of Revenue | -14.93% | -54.36% | |||
| Gross Profit | -5.67% | 248.51% | |||
| SG&A Expenses | -15.42% | -55.07% | |||
| Depreciation & Amortization | 0.09% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.62% | -53.78% | |||
| Operating Income | 29.69% | 81.33% | |||
| Income Before Tax | -170.18% | 175.97% | |||
| Income Tax Expenses | -3,238.46% | -- | |||
| Earnings from Continuing Operations | -161.14% | 175.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 149.04% | -110.97% | |||
| Net Income | -167.30% | -62.22% | |||
| EBIT | 29.69% | 81.33% | |||
| EBITDA | 35.76% | 83.99% | |||
| EPS Basic | -251.22% | -72.85% | |||
| Normalized Basic EPS | -118.02% | 307.04% | |||
| EPS Diluted | -285.45% | -75.56% | |||
| Normalized Diluted EPS | -121.88% | 271.94% | |||
| Average Basic Shares Outstanding | 11.52% | 1.36% | |||
| Average Diluted Shares Outstanding | -8.21% | 10.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||